Mobile, Ala. – In a major milestone for cancer care and medical innovation, Urology Associates has become the first urology practice in the United States to offer Vabrinty, a groundbreaking injectable treatment for patients with prostate cancer.

The new therapy, Vabrinty, is an Androgen Deprivation Therapy (ADT) injection. The injection works by lowering or blocking male hormones, such as testosterone, that can drive the growth of prostate cancer cells. By bringing this treatment to Mobile first, Urology Associates is placing the region at the forefront of prostate cancer care nationwide.

“This is a significant advancement not only for our practice, but for the patients and families we serve throughout the Gulf Coast region,” said Dr. Reardon. “Offering the latest treatment options close to home means our patients can access innovative care without leaving their community.”

The first patient in the country to receive Vabrinty in a urology practice setting was treated at Urology Associates under Dr. Reardon’s care, marking a historic moment for both the practice and patients along the Gulf Coast.

As prostate cancer remains one of the most commonly diagnosed cancers in men, access to new and effective treatment options is critical. Urology Associates continues to lead the way by expanding innovative services and advancing the standard of care for patients across the region.

Urology Associates has long been recognized for its commitment to advancing urologic and cancer care services. This latest milestone further reinforces the practice’s role as a leader in bringing innovative treatment options to the community.

For more information about prostate cancer treatment options or to schedule an appointment, please contact Urology Associates at (251) 433-1895 or visit https://link.edgepilot.com/s/d1bcb71e/BRWcnYsX70GbPEzCbhPtOA?u=http://www.uampa.com/.